Zunsemetinib: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies 0% 1 20 Improvement, Studies, Patients Relative Risk Mortality 0% 1 20 RCTs 0% 1 20 Late 0% 1 20 Zunsemetinib for COVID-19 c19early.org December 2025 Favorszunsemetinib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gan (DB RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 zunsemetinib COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors zunsemetinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gan (DB RCT) 0% 1.00 [0.07-13.9] 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 zunsemetinib COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors zunsemetinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gan (DB RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 zunsemetinib COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors zunsemetinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gan (DB RCT) 0% 1.00 [0.07-13.9] 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 zunsemetinib COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors zunsemetinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gan (DB RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Gan (DB RCT) -25% 1.25 [0.47-3.33] progression 5/10 4/10 Gan (DB RCT) -100% 2.00 [0.21-18.7] progression 2/10 1/10 Zunsemetinib COVID-19 outcomes c19early.org December 2025 Favors zunsemetinib Favors control